vs
Side-by-side financial comparison of Regencell Bioscience Holdings Ltd (RGC) and Tilray Brands, Inc. (TLRY). Click either name above to swap in a different company.
Regencell Bioscience Holdings Ltd is a specialized bioscience enterprise focused on the research, development and commercialization of therapeutic products derived from traditional Chinese medicine. Its core pipeline targets neurodegenerative, immunological and infectious disease treatments, with primary operating markets across Greater China and other Asian regions.
Tilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand, and Latin America, with growing facilities in Germany and Portugal.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $217.5M | ||
| Q3 25 | — | $209.5M | ||
| Q2 25 | — | $224.5M | ||
| Q1 25 | — | $185.8M | ||
| Q4 24 | — | $210.9M | ||
| Q3 24 | — | $200.0M | ||
| Q2 24 | — | $229.9M | ||
| Q1 24 | — | $188.3M |
| Q4 25 | — | $-44.9M | ||
| Q3 25 | — | $-322.0K | ||
| Q2 25 | — | $-1.3B | ||
| Q1 25 | — | $-789.4M | ||
| Q4 24 | — | $-85.3M | ||
| Q3 24 | — | $-39.2M | ||
| Q2 24 | — | $-31.7M | ||
| Q1 24 | — | $-92.7M |
| Q4 25 | — | 26.4% | ||
| Q3 25 | — | 27.4% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 28.0% | ||
| Q4 24 | — | 29.0% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | — | 35.8% | ||
| Q1 24 | — | 26.2% |
| Q4 25 | — | -10.2% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | -643.1% | ||
| Q1 25 | — | -409.0% | ||
| Q4 24 | — | -20.0% | ||
| Q3 24 | — | -18.3% | ||
| Q2 24 | — | -7.2% | ||
| Q1 24 | — | -43.6% |
| Q4 25 | — | -20.7% | ||
| Q3 25 | — | -0.2% | ||
| Q2 25 | — | -566.9% | ||
| Q1 25 | — | -424.9% | ||
| Q4 24 | — | -40.5% | ||
| Q3 24 | — | -19.6% | ||
| Q2 24 | — | -13.8% | ||
| Q1 24 | — | -49.2% |
| Q4 25 | — | $-0.41 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $7.26 | ||
| Q1 25 | — | $-8.69 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-0.04 | ||
| Q2 24 | — | $-0.04 | ||
| Q1 24 | — | $-0.12 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
